We are live on ! Find out more
PRTK

Paratek Pharmaceuticals, Inc.

Delisted

PRTK was delisted on the 20th of September, 2023.

84 hedge funds and large institutions have $44.4M invested in Paratek Pharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 31 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more call options, than puts

Call options by funds: $173K | Put options by funds: $99K

16% less funds holding

Funds holding: 10084 (-16)

32% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 31

46% less capital invested

Capital invested by funds: $82.1M → $44.4M (-$37.7M)

50% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 28

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
84
Holders Change
-16
Holders Change %
-16%
% of All Funds
1.42%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
14
Increased
21
Reduced
31
Closed
28
Calls
$173K
Puts
$99K
Net Calls
+$74K
Net Calls Change
+$209K

PRTK Hedge Fund Activity: Q2 2022 in Review

84 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q2 2022, worth a combined $44.4M — down 46% from $82.1M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of PRTK and 14 opened new positions — a net loss of 14 holders — while 31 trimmed existing stakes and 21 added.

The largest buyer was Millennium Management, adding an estimated $755K. The largest seller was BlackRock, cutting an estimated $4.52M.

  • 84 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q2 2022, down from 100 in Q1 2022.
  • Funds reported $44.4M of Paratek Pharmaceuticals, Inc. stock for Q2 2022, down 46% quarter-over-quarter.
  • 14 funds opened new Paratek Pharmaceuticals, Inc. positions in Q2 2022 and 28 closed out, a net change of -14 holders.
  • The largest Paratek Pharmaceuticals, Inc. buyer in Q2 2022 was Millennium Management, an estimated $755K added.
  • The largest Paratek Pharmaceuticals, Inc. seller in Q2 2022 was BlackRock, an estimated $4.52M sold.

Based on aggregated 13F filings for Q2 2022.